Isn't the Motley Fool article the second time that some idiot tried to say PGNX is ready to plunge? The last time came when PGNX reached $5, and now this one comes out the day after a big rise. That rise was triggered by the FDA agreeing to create an advisory board to review the sNDA for Relistor in chronic pain. The author of that Motley Fool article wrote that Relistor was dead, but the chronic pain market is the biggest one out there for Relistor, so saying it is dead is ludicrous. It may be in the ICU, but it sure isn't dead. Sounds like attempted manipulation by a short to me. In any event. all that matter regarding Relistor is what the advisory board says.